"The CSL Student Conference was started in 2006 and, through the years, has been organized by graduate students in CSL. The first edition primarily focused on the areas of Communication, Control, and ...

Greg Leyh likes to screw around with voltage and electric fields and plasma. In his time he's built some of the world's biggest Tesla coils, huge towering transformers that throw off terrifying webs ...

Analysing the top 10 tech company logos, we can understand the art and science behind creating visual identities that stand out from the crowd. Most people scroll past logos like they're invisible.

Jarden analyst Steven Wheen maintained a Buy rating on CSL (CMXHF – Research Report) on February 3 and set a price target of A$329.62. The company’s shares closed last Monday at $161.37.

Innovative fertilizer management practices, such as treating slurry with plasma induction, show promise for reducing carbon and nitrogen losses, but its impact on greenhouse gas (GHG) emissions needs ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

Fans of the Papirus icon theme for Linux desktops will be happy hear a new version is now available to download. Retro gaming fans will appreciate an expansion in mime type support in this update.

Learn More CSL Ltd (ASX: CSL) shares couldn't avoid the broader market sell-off on Monday. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock ended the day down 1.4%, trading for $276.42 apiece.

On Monday, three logos were revealed to the public, one for each potential nickname, but NHL fans weren't particularly impressed by the latest round of options. Much of the criticism was focused ...

10 luxury brand logos have mastered it. They've become more than marks on products—they're cultural touchstones, over decades and continents. Logos are stories we tell ourselves. The best ones?

Learn More If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.

It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus ...